A team of researchers is calling for clinical trials of hospitalized COVID-19 patients after a drug used to treat cholesterol was found to reduce coronavirus infection by 70% in laboratory studies, a new report said
According to the report, the results of the journal Frontiers in Pharmacology, published on Friday by researchers from the UK and Italy, showed that fenofibrate and Fenofibic acid resulted in a significant reduction in coronavirus infection in human cells when the drug was used in safe and approved concentrations, according to a press release on Friday.
“Our data suggest that fenofibrate may have the potential to reduce the severity of COVID-19 symptoms as well as the spread of the virus,” said Dr. Elisa Vicenzi from the San Raffaele Scientific Institute in Milan and co-author of the press release. “Given that fenofibrate is a very cheap and globally available oral drug, along with its longstanding clinical use and good safety profile, our data have a global impact.”
According to the study, fenofibrate and Fenofibic acid is believed to work by inhibiting the harmful overproduction of cytokines associated with coronavirus infection, treating airway inflammation, and preventing the clotting of blood seen in many late-stage COVID-19 patients. FOX 10 reported.
According to the report, the research team is calling for additional clinical trials to investigate the drug’s use as a potential COVID-19 therapy while trials at the University of Pennsylvania and the Hebrew University of Jerusalem are ongoing.
Copyright 2021 by KPRC Click2Houston – All rights reserved.